West Pharmaceutical Services, Inc. (NYSE:WST) CEO Eric Mark Green Sells 44,000 Shares

West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) CEO Eric Mark Green sold 44,000 shares of the company’s stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $238.99, for a total transaction of $10,515,560.00. Following the transaction, the chief executive officer now owns 114,922 shares in the company, valued at approximately $27,465,208.78. The sale was disclosed in a filing with the SEC, which is available at this link.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $236.03 on Friday. The company’s fifty day moving average price is $237.21 and its 200 day moving average price is $280.74. West Pharmaceutical Services, Inc. has a 1 year low of $206.19 and a 1 year high of $475.00. The company has a market capitalization of $17.47 billion, a PE ratio of 28.47, a price-to-earnings-growth ratio of 1.91 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.89 and a current ratio of 3.80.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its quarterly earnings results on Thursday, October 27th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.12 by ($0.09). West Pharmaceutical Services had a return on equity of 28.15% and a net margin of 21.68%. The firm had revenue of $686.90 million for the quarter, compared to analysts’ expectations of $730.64 million. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 8.18 earnings per share for the current year.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 16th. Shareholders of record on Wednesday, November 9th were given a dividend of $0.19 per share. The ex-dividend date of this dividend was Tuesday, November 8th. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.18. This represents a $0.76 dividend on an annualized basis and a yield of 0.32%. West Pharmaceutical Services’s dividend payout ratio is currently 9.17%.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. UBS Group initiated coverage on shares of West Pharmaceutical Services in a research note on Wednesday, November 30th. They set a “neutral” rating and a $250.00 price target on the stock. Bank of America downgraded shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $385.00 to $250.00 in a report on Friday, October 28th. KeyCorp dropped their price objective on shares of West Pharmaceutical Services from $350.00 to $315.00 and set an “overweight” rating on the stock in a report on Friday, December 2nd. Finally, StockNews.com initiated coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Hold” and a consensus price target of $271.67.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently added to or reduced their stakes in the stock. CX Institutional acquired a new position in West Pharmaceutical Services during the second quarter worth $28,000. Guardian Wealth Advisors LLC acquired a new position in West Pharmaceutical Services during the third quarter worth $29,000. Householder Group Estate & Retirement Specialist LLC acquired a new position in West Pharmaceutical Services during the third quarter worth $36,000. Allworth Financial LP raised its position in shares of West Pharmaceutical Services by 70.8% in the second quarter. Allworth Financial LP now owns 123 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 51 shares during the last quarter. Finally, Private Trust Co. NA raised its position in shares of West Pharmaceutical Services by 194.6% in the third quarter. Private Trust Co. NA now owns 165 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 109 shares during the last quarter. 91.98% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

(Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.